 |
|
|
| |
Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naďve Patients With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6 Infection and Compensated Cirrhosis: EXPEDITION-8 Complete Results
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Robert S Brown Jr1, Maria Buti2, Lino Rodrigues Jr3, Vladimir Chulanov4,5, Wan-Long Chuang6, Humberto Aguilar7, Gábor Horváth8, Elimelech Zuckerman9, Barbara Rosado Carrion10, Federico Rodriguez-Perez11, Petr Urbánek12, Armand Abergel13, Eric Cohen3, Sandra S Lovell3, Gretja Schnell3, Chih-Wei Lin3*, Jiuhong Zha3, Stanley Wang3, Roger Trinh3, Federico J Mensa3, Margaret Burroughs3, Franco Felizarta141Weill Cornell Medical College, Center for Liver Disease and Transplantation, New York, New York, United States; 2Vall d'Hebron University Hospital and CiBERHED del Instituto Carlos III, Barcelona, Spain; 3AbbVie Inc., North Chicago, Illinois, United States; 4Central Research Institute of Epidemiology, Reference Center for Viral Hepatitis, Moscow, Russia; 5Sechenov First Moscow State Medical University, Moscow, Russia; 6Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 7Louisiana Research Center, Shreveport, Louisiana, United States; 8Hepatology Center of Buda, Budapest, Hungary; 9Liver Unit, Carmel Medical Center, Faculty of Medicine, Technion Institute, Haifa, Israel; 10Director of GHGCPR Research Institute, Ponce, Puerto Rico; 11Klinical Investigations Group, San Juan, Puerto Rico; 12Charles University and Central Military Hospital, Prague, Czech Republic; 13CHU Estaing University Hospital, Clermont-Ferrand, France; 14Private Practice, Bakersfield, California, United States. *Current employee of Amgen Inc., Thousand Oaks, California, USA
|
| |
|
|
|
|
|
